Trial Profile
A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2012 Status changed from recruiting to active, no longer recruiting reported by ClinicalTrials.gov.
- 06 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.